240 related articles for article (PubMed ID: 22080057)
21. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
Li L; Liu C; Amato RJ; Chang JT; Du G; Li W
Oncotarget; 2014 Nov; 5(21):10840-53. PubMed ID: 25333262
[TBL] [Abstract][Full Text] [Related]
22. The role of epithelial mesenchymal transition markers in thyroid carcinoma progression.
Montemayor-Garcia C; Hardin H; Guo Z; Larrain C; Buehler D; Asioli S; Chen H; Lloyd RV
Endocr Pathol; 2013 Dec; 24(4):206-12. PubMed ID: 24126800
[TBL] [Abstract][Full Text] [Related]
23. Metaplastic breast carcinoma: pathology and clinical outcome.
Bellino R; Arisio R; D'Addato F; Attini R; Durando A; Danese S; Bertone E; Grio R; Massobrio M
Anticancer Res; 2003; 23(1B):669-73. PubMed ID: 12680165
[TBL] [Abstract][Full Text] [Related]
24. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
25. Laminin 5 expression in metaplastic breast carcinomas.
Carpenter PM; Wang-Rodriguez J; Chan OT; Wilczynski SP
Am J Surg Pathol; 2008 Mar; 32(3):345-53. PubMed ID: 18300817
[TBL] [Abstract][Full Text] [Related]
26. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2.
Ma P; Ni K; Ke J; Zhang W; Feng Y; Mao Q
Exp Biol Med (Maywood); 2018 Mar; 243(5):473-480. PubMed ID: 29368542
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of CD44
Da Cruz Paula A; Leitão C; Marques O; Rosa AM; Santos AH; Rêma A; de Fátima Faria M; Rocha A; Costa JL; Lima M; Lopes C
Virchows Arch; 2017 Mar; 470(3):311-322. PubMed ID: 28116522
[TBL] [Abstract][Full Text] [Related]
28. Expression of BMI1 and ZEB1 in epithelial-mesenchymal transition of tongue squamous cell carcinoma.
Kurihara K; Isobe T; Yamamoto G; Tanaka Y; Katakura A; Tachikawa T
Oncol Rep; 2015 Aug; 34(2):771-8. PubMed ID: 26043676
[TBL] [Abstract][Full Text] [Related]
29. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.
Buehler D; Hardin H; Shan W; Montemayor-Garcia C; Rush PS; Asioli S; Chen H; Lloyd RV
Mod Pathol; 2013 Jan; 26(1):54-61. PubMed ID: 22899291
[TBL] [Abstract][Full Text] [Related]
30. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.
Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
Mol Oncol; 2014 May; 8(3):565-80. PubMed ID: 24508063
[TBL] [Abstract][Full Text] [Related]
31. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.
Toll A; Masferrer E; Hernández-Ruiz ME; Ferrandiz-Pulido C; Yébenes M; Jaka A; Tuneu A; Jucglà A; Gimeno J; Baró T; Casado B; Gandarillas A; Costa I; Mojal S; Peña R; de Herreros AG; García-Patos V; Pujol RM; Hernández-Muñoz I
J Dermatol Sci; 2013 Nov; 72(2):93-102. PubMed ID: 23928229
[TBL] [Abstract][Full Text] [Related]
32. IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways.
Zhang Z; Yang M; Chen R; Su W; Li P; Chen S; Chen Z; Chen A; Li S; Hu C
Oncogene; 2014 Jun; 33(26):3374-82. PubMed ID: 23975422
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Mahmud Z; Asaduzzaman M; Kumar U; Masrour N; Jugov R; Coombes RC; Shousha S; Hu Y; Lam EW; Yagüe E
Biochem Pharmacol; 2019 May; 163():391-403. PubMed ID: 30862505
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
[TBL] [Abstract][Full Text] [Related]
35. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of snail in metaplastic breast carcinoma.
Nassar A; Sookhan N; Santisteban M; Bryant SC; Boughey JC; Giorgadze T; Degnim A
Diagn Pathol; 2010 Nov; 5():76. PubMed ID: 21110878
[TBL] [Abstract][Full Text] [Related]
37. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.
Yamada N; Sugai T; Eizuka M; Tsuchida K; Sugimoto R; Mue Y; Suzuki M; Osakabe M; Uesugi N; Ishida K; Otsuka K; Matsumoto T
Hum Pathol; 2017 Feb; 60():151-159. PubMed ID: 27836787
[TBL] [Abstract][Full Text] [Related]
38. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance.
Zhang P; Sun Y; Ma L
Cell Cycle; 2015; 14(4):481-7. PubMed ID: 25607528
[TBL] [Abstract][Full Text] [Related]
39. The prognostic role of the epithelial-mesenchymal transition markers E-cadherin and Slug in laryngeal squamous cell carcinoma.
Cappellesso R; Marioni G; Crescenzi M; Giacomelli L; Guzzardo V; Mussato A; Staffieri A; Martini A; Blandamura S; Fassina A
Histopathology; 2015 Oct; 67(4):491-500. PubMed ID: 25684546
[TBL] [Abstract][Full Text] [Related]
40. β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast.
Lacroix-Triki M; Geyer FC; Lambros MB; Savage K; Ellis IO; Lee AH; Reis-Filho JS
Mod Pathol; 2010 Nov; 23(11):1438-48. PubMed ID: 20693983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
